BridgeBio Pharma will present ten digital posters on Acoramidis at AHA Scientific Sessions 2025 in New Orleans.
Quiver AI Summary
BridgeBio Pharma, Inc. announced that ten moderated digital posters related to its treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) will be presented at the American Heart Association Scientific Sessions 2025 in New Orleans from November 7-10. The posters will cover various findings from the ATTRibute-CM study, including the effectiveness of their drug, Acoramidis, in reducing all-cause mortality and cardiovascular hospitalizations among patients with the disease. Several physicians from prestigious institutions will present results on topics such as demographic and geographic disparities in treatment outcomes and the association of serum transthyretin levels with cardiovascular health. Acoramidis is a transthyretin stabilizer approved for treating ATTR-CM in adults. BridgeBio is committed to developing transformative medicines for genetic diseases and continues to grow its pipeline of treatments.
Potential Positives
- BridgeBio Pharma will present ten moderated digital posters at the American Heart Association (AHA) Scientific Sessions 2025, showcasing significant research findings related to their product, Acoramidis.
- The research highlights Acoramidis' efficacy in reducing all-cause mortality and cardiovascular-related hospitalizations in patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), which is a key advancement in treatment options for this condition.
- Participation in a prominent medical conference like the AHA Scientific Sessions enhances BridgeBio's visibility and credibility in the biopharmaceutical field, potentially attracting attention from healthcare professionals and investors.
Potential Negatives
- The mention of adverse reactions such as diarrhea and upper abdominal pain associated with Attruby may raise concerns about the safety profile of the drug, potentially affecting physician and patient confidence.
- Significant demographic and geographic disparities in treatment outcomes may reflect a need for improved access and equality in healthcare, which could be viewed as a failing on the part of the company to ensure broad effectiveness of its therapies.
- The need to present findings at a scientific conference suggests that there may be ongoing uncertainty regarding the drug's efficacy and acceptance within the medical community.
FAQ
What is the focus of BridgeBio Pharma?
BridgeBio Pharma specializes in developing biopharmaceuticals targeting genetic diseases, aiming to provide transformative treatments for patients.
When will BridgeBio present at the AHA Scientific Sessions 2025?
BridgeBio will present ten moderated digital posters at the AHA Scientific Sessions from November 7 to 10, 2025.
What is Attruby™ (acoramidis) used for?
Attruby is indicated for treating transthyretin-mediated amyloidosis cardiomyopathy to reduce cardiovascular death and hospitalization in adults.
Who will be presenting the research at the AHA event?
Research will be presented by notable doctors from various institutions, including Marianna Fontana, Prem Soman, and Richard Cheng.
What are common side effects of Attruby?
Common side effects of Attruby include diarrhea and upper abdominal pain, which are generally mild and resolve without discontinuation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/22, 08/08 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 58 times in the past 6 months. Of those trades, 0 have been purchases and 58 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- GENETIC DISORDER L.P. KKR sold 6,000,000 shares for an estimated $205,200,000
- GLOBAL INVESTORS LP VIKING sold 3,500,000 shares for an estimated $154,000,000
- FRANK MCCORMICK has made 0 purchases and 8 sales selling 374,000 shares for an estimated $21,669,536.
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 35 sales selling 447,312 shares for an estimated $20,290,345.
- CHARLES J HOMCY has made 0 purchases and 3 sales selling 300,000 shares for an estimated $13,912,442.
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 3 sales selling 59,590 shares for an estimated $2,961,803.
- ANDREA ELLIS sold 17,167 shares for an estimated $841,183
- HANNAH VALANTINE has made 0 purchases and 5 sales selling 8,999 shares for an estimated $379,007.
- MARICEL APULI (Chief Accounting Officer) sold 1,000 shares for an estimated $45,440
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBIO Hedge Fund Activity
We have seen 210 institutional investors add shares of $BBIO stock to their portfolio, and 147 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 6,000,000 shares (-31.2%) from their portfolio in Q2 2025, for an estimated $259,080,000
- VIKING GLOBAL INVESTORS LP removed 3,500,000 shares (-15.9%) from their portfolio in Q2 2025, for an estimated $151,130,000
- CITADEL ADVISORS LLC removed 2,598,708 shares (-88.7%) from their portfolio in Q2 2025, for an estimated $112,212,211
- FARALLON CAPITAL MANAGEMENT LLC added 2,169,000 shares (+37.8%) to their portfolio in Q2 2025, for an estimated $93,657,420
- JANUS HENDERSON GROUP PLC added 2,105,133 shares (+29.4%) to their portfolio in Q2 2025, for an estimated $90,899,642
- MACQUARIE GROUP LTD added 2,003,713 shares (+2189.3%) to their portfolio in Q2 2025, for an estimated $86,520,327
- D. E. SHAW & CO., INC. added 1,998,104 shares (+2403.0%) to their portfolio in Q2 2025, for an estimated $86,278,130
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- Goldman Sachs issued a "Buy" rating on 10/31/2025
- Piper Sandler issued a "Overweight" rating on 10/30/2025
- Cantor Fitzgerald issued a "Overweight" rating on 10/30/2025
- TD Cowen issued a "Buy" rating on 10/30/2025
- Raymond James issued a "Outperform" rating on 10/30/2025
- Truist Securities issued a "Buy" rating on 10/30/2025
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 16 analysts offer price targets for $BBIO in the last 6 months, with a median target of $73.5.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $90.0 on 11/03/2025
- Paul Choi from Goldman Sachs set a target price of $100.0 on 10/31/2025
- Tyler Van Buren from TD Cowen set a target price of $95.0 on 10/30/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $110.0 on 10/30/2025
- Danielle Brill from Truist Securities set a target price of $80.0 on 10/30/2025
- Martin Auster from Raymond James set a target price of $71.0 on 10/30/2025
- Biren Amin from Piper Sandler set a target price of $98.0 on 10/30/2025
Full Release
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans, LA from November 7 - 10, 2025.
Moderated Digital Posters:
Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings from the ATTRibute-CM Study
Presenter:
Marianna Fontana, M.D., University College London, UK
Date/time:
Saturday, November 8 at 3:15 pm CT
Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results from the ATTRibute-CM Study
Presenter:
Prem Soman, M.D., Ph.D., University of Pittsburgh School of Medicine, U.S.
Date/time:
Saturday, November 8 at 9:15 am CT
Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient Subgroups
Presenter:
Lily Stern, M.D., Cedars-Sinai Heart Institute, U.S.
Date/time:
Saturday, November 8 at 3:15 pm CT
Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants with Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation Status
Presenter:
Mathew Maurer, M.D., Columbia University Irving Medical Center, U.S.
Date/time:
Saturday, November 8 at 9:15 am CT
Demographic Disparities in Tafamidis Treatment and Clinical Outcomes Across the United States
Presenter:
Nicole Cyrille-Superville, M.D., Atrium Health Sanger Heart & Vascular Institute Kenilworth, Charlotte, NC, U.S.
Date/time:
Saturday, November 8 at 12:15 pm CT
Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States Veterans
Presenter:
Sandesh Dev, M.D., Southern Arizona VA Health Care System, U.S.
Date/time:
Saturday, November 8 at 3:15 pm CT
Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights from the ATTRibute-CM Study
Presenter:
Nitasha Sarswat, M.D., UChicago Medicine, U.S.
Date/time:
Sunday, November 9 at 3:15 pm CT
Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients with Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Presenter:
Richard Cheng, M.D., University of Washington, Seattle, WA, U.S.
Date/time:
Sunday, November 9 at 3:15 pm CT
Acoramidis Reduces the Risk of All-Cause Mortality and Cardiovascular-Related Hospitalization Compared with Placebo in Participants with Transthyretin Amyloid Cardiomyopathy and Early-Stage Heart Failure Regardless of Atrial Fibrillation History: Insights from ATTRibute-CM
Presenter:
Ronald Witteles, M.D., Stanford University School of Medicine, U.S.
Date/time:
Saturday, November 8 at 3:15 pm CT
Vutrisiran Healthcare Resource Utilization, Costs, Discontinuation, and Mortality: A Retrospective Database Analysis
Presenter:
Nicole Bart, M.D., Ph.D., St Vincent's Hospital Sydney, AU
Date/time:
Monday, November 10 at 10:45 am CT
About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
About BridgeBio
BridgeBio Pharma (BridgeBio; Nasdaq: BBIO) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit
bridgebio.com
and follow us on
LinkedIn
,
X
,
Facebook
,
Instagram
, and
YouTube
.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
[email protected]
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]
